Physician profile
Dan Douer
NPI 1700825171
$476,873.44
in general payments reported to CMS, 2019-2025
11 companies · $2,210 in 2025
The $2,210 reported for 2025 was more than what a typical Hematology (Internal Medicine) provider received nationally (typical 2025 total: $1,177).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $177K · 2020: $119K · 2021: $61K · 2022: $84K · 2023: $21K · 2024: $13K · 2025: $2,210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $14K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $13K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,300 · Travel and Lodging: $2,523 · Food and Beverage: $952.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $13,760.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $12,580.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,300.00 |
| Travel and Lodging | $2,523.00 |
| Food and Beverage | $951.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $250,734.28 | 2019-2024 | Blincyto |
| Servier Pharmaceuticals LLC | $145,527.20 | 2019-2024 | |
| Servier Affaires Medicales | $37,299.93 | 2020-2021 | |
| Adaptive Biotechnologies Corporation | $21,901.56 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $11,411.77 | 2019-2023 | |
| Kite Pharma, INC. | $6,571.28 | 2019 | |
| Servier Bioinnovation | $2,210.00 | 2025 | Asparlas |
| Aurobindo Pharma USA, INC. | $550.00 | 2020 | |
| Btg International INC. | $542.80 | 2023-2024 | |
| Azurity Pharmaceuticals, INC. | $110.23 | 2024 | |
| Legend Biotech USA INC. | $14.39 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dan Douer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.